Zacks Investment Research upgraded shares of Bellerophon Therapeutics (NASDAQ:BLPH) from a hold rating to a buy rating in a research note published on Friday morning, Zacks.com reports. The brokerage currently has $0.75 price target on the biotechnology company’s stock.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

Other equities research analysts have also issued reports about the stock. Maxim Group set a $3.00 price objective on shares of Bellerophon Therapeutics and gave the company a buy rating in a research note on Monday, April 8th. HC Wainwright reaffirmed a buy rating and issued a $3.00 price objective on shares of Bellerophon Therapeutics in a research note on Tuesday, January 29th. Finally, ValuEngine lowered shares of Bellerophon Therapeutics from a buy rating to a hold rating in a research note on Thursday, December 20th.

NASDAQ:BLPH opened at $0.65 on Friday. Bellerophon Therapeutics has a 52 week low of $0.47 and a 52 week high of $3.30. The firm has a market capitalization of $44.86 million, a PE ratio of -1.91 and a beta of -0.01.

Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.10. On average, sell-side analysts anticipate that Bellerophon Therapeutics will post -0.52 earnings per share for the current year.

In related news, Director Naseem Amin bought 571,429 shares of the company’s stock in a transaction that occurred on Friday, January 25th. The shares were bought at an average price of $0.70 per share, for a total transaction of $400,000.30. Following the transaction, the director now directly owns 1,818,867 shares of the company’s stock, valued at $1,273,206.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 53.10% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC lifted its position in shares of Bellerophon Therapeutics by 60.2% during the 4th quarter. Virtu Financial LLC now owns 36,708 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 13,799 shares during the period. Geode Capital Management LLC lifted its position in shares of Bellerophon Therapeutics by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 27,027 shares during the period. Vanguard Group Inc lifted its position in shares of Bellerophon Therapeutics by 2.5% during the 3rd quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock valued at $1,105,000 after acquiring an additional 25,300 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Bellerophon Therapeutics by 4.7% during the 3rd quarter. Renaissance Technologies LLC now owns 1,213,276 shares of the biotechnology company’s stock valued at $1,310,000 after acquiring an additional 54,076 shares during the period. Institutional investors own 47.63% of the company’s stock.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Further Reading: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.